Skip to main content
Erschienen in: Clinical Rheumatology 1/2024

15.11.2023 | ORIGINAL ARTICLE

Disease activity is associated with changes in the innate immune function in patients with systemic lupus erythematosus

verfasst von: Jiram Torres-Ruiz, Marina Rull-Gabayet, Nancy R. Mejía-Domínguez, Daniel Alberto Carrillo-Vázquez, Juan Alberto Reyes-Islas, Fabiola Cassiano-Quezada, Jennifer Cuellar-Rodríguez, Juan Sierra-Madero, Jessica Márquez Sánchez, Jesús Salvador Serrano-García, Alexia Esquinca González, Guillermo Juárez-Vega, Miguel Tapia-Rodríguez, Diana Gómez-Martín

Erschienen in: Clinical Rheumatology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Objective

To address the relationship between systemic lupus erythematosus (SLE) disease activity and the functional parameters of the innate immunity.

Methods

We evaluated a cohort of 26 adult SLE patients and 10 sex and age-paired healthy donors. When the patients had a disease flare (baseline) and when they achieve clinical response (follow-up), we assessed the systemic lupus erythematosus disease activity index 2 K (SLEDAI 2 K) and the following parameters with flow cytometry and confocal microscopy: monocyte subsets, their expression of TLR2, phagocytic monocytes and neutrophils using the pHrodo Red E. coli BioParticles, the respiratory burst with 123-dihydrorhodamine in neutrophils, and the spontaneous and lipopolysaccharide (LPS)-induced production of neutrophil extracellular traps (NETs). We used the Wilcoxon test to compare the paired medians with interquartile range (IQR) and the Mann–Whitney U test for independent medians. To assess the effect of prednisone and SLEDAI 2 K on the mentioned parameters, we applied a generalized mixed linear model.

Results

Twenty-three patients (88.4%) were women. The SLEDAI 2 K was higher at baseline 8 (6–14) in comparison to that at follow-up (6 (4–8), P = 0.028). At baseline, SLE patients had a decreased percentage of intermediate monocytes, a higher expression of TLR2 in total monocytes, increased phagocytosis in monocytes and neutrophils, a decreased respiratory burst intensity, and an increased production of NETs. In the mix model, the SLEDAI 2 K was the main factor influencing these functional innate immune parameters.

Conclusion

Disease activity regulates the innate immune function in SLE which may contribute to the clinical features and infection predisposition.
Key points
This is the first cohort study addressing the effect of disease activity and prednisone use on the innate immune function of lupus patients.
Our results show that the disease activity is a key regulator of the respiratory burst, phagocytosis, and the production of neutrophil extracellular traps.
Also, we observed a differential proportion of monocyte subsets according to SLE disease activity.
We consider that our manuscript contributes to the evidence addressing the intrinsic immune abnormalities of patients with SLE regardless of the use of immunosuppressants and set the bases for new research work considering the disease activity as an element to decide the prescription and duration of antibiotic prophylaxis in SLE patients, which is of interest to all rheumatologists.
Literatur
1.
Zurück zum Zitat Weidenbusch M, Kulkarni OP, Anders HJ (2017) The innate immune system in human systemic lupus erythematosus. Clin Sci 131(8):625–634CrossRef Weidenbusch M, Kulkarni OP, Anders HJ (2017) The innate immune system in human systemic lupus erythematosus. Clin Sci 131(8):625–634CrossRef
2.
Zurück zum Zitat Lo MS, Tsokos GC (2018) Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy. Curr Opin Rheumatol 30(2):222–228CrossRefPubMedPubMedCentral Lo MS, Tsokos GC (2018) Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy. Curr Opin Rheumatol 30(2):222–228CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Bosch X, Guilabert A, Pallares L, Cervera R, Ramos-Casals M, Bove A et al (2006) Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 15(9):584–589CrossRefPubMed Bosch X, Guilabert A, Pallares L, Cervera R, Ramos-Casals M, Bove A et al (2006) Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 15(9):584–589CrossRefPubMed
4.
Zurück zum Zitat Torres-Ruiz J, Barrera-Vargas A, Ortiz-Hernandez R, Alcocer-Varela J, Ponce-de-Leon A, Gomez-Martin D (2018) Microbiological and immunological profile of patients with severe lupus flares related to bloodstream infections: a retrospective cohort study. Lupus 27(2):312–318CrossRefPubMed Torres-Ruiz J, Barrera-Vargas A, Ortiz-Hernandez R, Alcocer-Varela J, Ponce-de-Leon A, Gomez-Martin D (2018) Microbiological and immunological profile of patients with severe lupus flares related to bloodstream infections: a retrospective cohort study. Lupus 27(2):312–318CrossRefPubMed
5.
Zurück zum Zitat Jeong SJ, Choi H, Lee HS, Han SH, Chin BS, Baek JH et al (2009) Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus. Scand J Infect Dis 41(4):268–274CrossRefPubMed Jeong SJ, Choi H, Lee HS, Han SH, Chin BS, Baek JH et al (2009) Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus. Scand J Infect Dis 41(4):268–274CrossRefPubMed
6.
Zurück zum Zitat Merayo-Chalico J, Gomez-Martin D, Pineirua-Menendez A, Santana-De Anda K, Alcocer-Varela J (2013) Lymphopenia as risk factor for development of severe infections in patients with systemic lupus erythematosus: a case-control study. QJM 106(5):451–457CrossRefPubMed Merayo-Chalico J, Gomez-Martin D, Pineirua-Menendez A, Santana-De Anda K, Alcocer-Varela J (2013) Lymphopenia as risk factor for development of severe infections in patients with systemic lupus erythematosus: a case-control study. QJM 106(5):451–457CrossRefPubMed
7.
Zurück zum Zitat Fessler BJ (2002) Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol 16(2):281–291CrossRefPubMed Fessler BJ (2002) Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol 16(2):281–291CrossRefPubMed
8.
Zurück zum Zitat Iliopoulos AGTG (1996) Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 25(5):19CrossRef Iliopoulos AGTG (1996) Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 25(5):19CrossRef
9.
Zurück zum Zitat Torres-Ruiz J, Mejia-Dominguez NR, Zentella-Dehesa A, Ponce-de-Leon A, Morales-Padilla SR, Vazquez-Rodriguez R et al (2018) The systemic lupus erythematosus infection predictive index (LIPI): a clinical-immunological tool to predict infections in lupus patients. Front Immunol 9:3144CrossRefPubMed Torres-Ruiz J, Mejia-Dominguez NR, Zentella-Dehesa A, Ponce-de-Leon A, Morales-Padilla SR, Vazquez-Rodriguez R et al (2018) The systemic lupus erythematosus infection predictive index (LIPI): a clinical-immunological tool to predict infections in lupus patients. Front Immunol 9:3144CrossRefPubMed
11.
Zurück zum Zitat Gyimesi E, Kavai M, Kiss E, Csipo I, Szucs G, Szegedi G (1993) Triggering of respiratory burst by phagocytosis in monocytes of patients with systemic lupus erythematosus. Clin Exp Immunol 94(1):140–144CrossRefPubMedPubMedCentral Gyimesi E, Kavai M, Kiss E, Csipo I, Szucs G, Szegedi G (1993) Triggering of respiratory burst by phagocytosis in monocytes of patients with systemic lupus erythematosus. Clin Exp Immunol 94(1):140–144CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Boghossian SH, Isenberg DA, Wright G, Snaith ML, Segal AW (1984) Effect of high-dose methylprednisolone therapy on phagocyte function in systemic lupus erythematosus. Ann Rheum Dis 43(4):541–550CrossRefPubMedPubMedCentral Boghossian SH, Isenberg DA, Wright G, Snaith ML, Segal AW (1984) Effect of high-dose methylprednisolone therapy on phagocyte function in systemic lupus erythematosus. Ann Rheum Dis 43(4):541–550CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277CrossRefPubMed Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277CrossRefPubMed
14.
Zurück zum Zitat Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686CrossRefPubMedPubMedCentral Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH et al (2005) The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 142(12 Pt 1):953–962CrossRefPubMed Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH et al (2005) The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 142(12 Pt 1):953–962CrossRefPubMed
16.
Zurück zum Zitat Moosig F, Graf D, Knorr-Spahr A, Zeuner RA, Bottcher S, Schroder JO (2003) Monocyte and granulocyte phagocytosis of Escherichia coil particles in systemic lupus erythematosus is not reduced when compared to healthy controls. Lupus 12(6):490–492CrossRefPubMed Moosig F, Graf D, Knorr-Spahr A, Zeuner RA, Bottcher S, Schroder JO (2003) Monocyte and granulocyte phagocytosis of Escherichia coil particles in systemic lupus erythematosus is not reduced when compared to healthy controls. Lupus 12(6):490–492CrossRefPubMed
17.
Zurück zum Zitat Huang WN, Tso TK, Wu HC, Yang HF, Tsay GJ (2016) Impaired phagocytosis of apoptotic cell material in serologically active clinically quiescent patients with systemic lupus erythematosis. Int J Rheum Dis 19(12):1310–1316CrossRefPubMed Huang WN, Tso TK, Wu HC, Yang HF, Tsay GJ (2016) Impaired phagocytosis of apoptotic cell material in serologically active clinically quiescent patients with systemic lupus erythematosis. Int J Rheum Dis 19(12):1310–1316CrossRefPubMed
18.
Zurück zum Zitat Carli L, Tani C, Vagnani S, Signorini V, Mosca M (2015) Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: prevalence and clinical impact—a systematic literature review. Semin Arthritis Rheum 45(2):190–194CrossRefPubMed Carli L, Tani C, Vagnani S, Signorini V, Mosca M (2015) Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: prevalence and clinical impact—a systematic literature review. Semin Arthritis Rheum 45(2):190–194CrossRefPubMed
19.
Zurück zum Zitat Mistry P, Nakabo S, O’Neil L, Goel RR, Jiang K, Carmona-Rivera C et al (2019) Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci. U.S.A 116(50):25222–8ADSCrossRefPubMedPubMedCentral Mistry P, Nakabo S, O’Neil L, Goel RR, Jiang K, Carmona-Rivera C et al (2019) Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci. U.S.A 116(50):25222–8ADSCrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Cuitino L, Obreque J, Gajardo-Meneses P, Villarroel A, Crisostomo N, San Francisco IF et al (2019) Heme-oxygenase-1 is decreased in circulating monocytes and is associated with impaired phagocytosis and ROS production in lupus nephritis. Front Immunol 10:2868CrossRefPubMedPubMedCentral Cuitino L, Obreque J, Gajardo-Meneses P, Villarroel A, Crisostomo N, San Francisco IF et al (2019) Heme-oxygenase-1 is decreased in circulating monocytes and is associated with impaired phagocytosis and ROS production in lupus nephritis. Front Immunol 10:2868CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Toller-Kawahisa JE, Canicoba NC, Venancio VP, Kawahisa R, Antunes LM, Cunha TM et al (2015) Systemic lupus erythematosus onset in lupus-prone B6.MRL/lpr mice Is influenced by weight gain and Is preceded by an increase in neutrophil oxidative burst activity. Free Radic Biol Med 86:362–73CrossRefPubMed Toller-Kawahisa JE, Canicoba NC, Venancio VP, Kawahisa R, Antunes LM, Cunha TM et al (2015) Systemic lupus erythematosus onset in lupus-prone B6.MRL/lpr mice Is influenced by weight gain and Is preceded by an increase in neutrophil oxidative burst activity. Free Radic Biol Med 86:362–73CrossRefPubMed
22.
Zurück zum Zitat Tsai CY, Li KJ, Hsieh SC, Liao HT, Yu CL (2019) What’s wrong with neutrophils in lupus? Clin Exp Rheumatol 37(4):684–693PubMed Tsai CY, Li KJ, Hsieh SC, Liao HT, Yu CL (2019) What’s wrong with neutrophils in lupus? Clin Exp Rheumatol 37(4):684–693PubMed
23.
Zurück zum Zitat Wu Z, Zhang S, Zhao L, Fei Y, Wang L, Li J et al (2017) Upregulation of CD16- monocyte subsets in systemic lupus erythematous patients. Clin Rheumatol 36(10):2281–2287CrossRefPubMed Wu Z, Zhang S, Zhao L, Fei Y, Wang L, Li J et al (2017) Upregulation of CD16- monocyte subsets in systemic lupus erythematous patients. Clin Rheumatol 36(10):2281–2287CrossRefPubMed
24.
Zurück zum Zitat Mikolajczyk TP, Osmenda G, Batko B, Wilk G, Krezelok M, Skiba D et al (2016) Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus. Lupus 25(1):18–27CrossRefPubMed Mikolajczyk TP, Osmenda G, Batko B, Wilk G, Krezelok M, Skiba D et al (2016) Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus. Lupus 25(1):18–27CrossRefPubMed
25.
Zurück zum Zitat Burbano C, Vasquez G, Rojas M (2014) Modulatory effects of CD14+CD16++ monocytes on CD14++CD16- monocytes: a possible explanation of monocyte alterations in systemic lupus erythematosus. Arthritis Rheumatol 66(12):3371–3381CrossRefPubMed Burbano C, Vasquez G, Rojas M (2014) Modulatory effects of CD14+CD16++ monocytes on CD14++CD16- monocytes: a possible explanation of monocyte alterations in systemic lupus erythematosus. Arthritis Rheumatol 66(12):3371–3381CrossRefPubMed
26.
Zurück zum Zitat Barrera Garcia A, Gomez-Puerta JA, Arias LF, Burbano C, Restrepo M, Vanegas AL et al (2016) Infiltrating CD16(+) are associated with a reduction in peripheral CD14(+)CD16(++) monocytes and severe forms of lupus nephritis. Autoimmune Dis 2016:9324315PubMedPubMedCentral Barrera Garcia A, Gomez-Puerta JA, Arias LF, Burbano C, Restrepo M, Vanegas AL et al (2016) Infiltrating CD16(+) are associated with a reduction in peripheral CD14(+)CD16(++) monocytes and severe forms of lupus nephritis. Autoimmune Dis 2016:9324315PubMedPubMedCentral
27.
Zurück zum Zitat Nakatani K, Yoshimoto S, Iwano M, Asai O, Samejima K, Sakan H et al (2010) Fractalkine expression and CD16+ monocyte accumulation in glomerular lesions: association with their severity and diversity in lupus models. Am J Physiol Renal Physiol 299(1):F207–F216CrossRefPubMed Nakatani K, Yoshimoto S, Iwano M, Asai O, Samejima K, Sakan H et al (2010) Fractalkine expression and CD16+ monocyte accumulation in glomerular lesions: association with their severity and diversity in lupus models. Am J Physiol Renal Physiol 299(1):F207–F216CrossRefPubMed
28.
Zurück zum Zitat Migita K, Miyashita T, Maeda Y, Nakamura M, Yatsuhashi H, Kimura H et al (2007) Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol 34(3):493–500PubMed Migita K, Miyashita T, Maeda Y, Nakamura M, Yatsuhashi H, Kimura H et al (2007) Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol 34(3):493–500PubMed
30.
Zurück zum Zitat Perez-Ferro M, Serrano Del Castillo C, Sanchez-Pernaute O (2016) Cell membrane-bound TLR2 and TLR4: potential predictors of active systemic lupus erythematosus and lupus nephritis. J Rheumatol 43(7):1444–1445CrossRefPubMed Perez-Ferro M, Serrano Del Castillo C, Sanchez-Pernaute O (2016) Cell membrane-bound TLR2 and TLR4: potential predictors of active systemic lupus erythematosus and lupus nephritis. J Rheumatol 43(7):1444–1445CrossRefPubMed
31.
Zurück zum Zitat Feng X, Yang R, Tian Y, Miao X, Guo H, Gao F et al (2020) HMGB1 protein promotes glomerular mesangial matrix deposition via TLR2 in lupus nephritis. J Cell Physiol 235(6):5111–5119CrossRefPubMed Feng X, Yang R, Tian Y, Miao X, Guo H, Gao F et al (2020) HMGB1 protein promotes glomerular mesangial matrix deposition via TLR2 in lupus nephritis. J Cell Physiol 235(6):5111–5119CrossRefPubMed
32.
Zurück zum Zitat Feng XJ, Wu C, Yan GF, Liu QJ, Liu JX, Hao J et al (2016) TLR2 plays a critical role in HMGB1-induced glomeruli cell proliferation through the FoxO1 signaling pathway in lupus nephritis. J Interferon Cytokine Res : Off J Int Soc Interferon Cytokine Res 36(4):258–266CrossRef Feng XJ, Wu C, Yan GF, Liu QJ, Liu JX, Hao J et al (2016) TLR2 plays a critical role in HMGB1-induced glomeruli cell proliferation through the FoxO1 signaling pathway in lupus nephritis. J Interferon Cytokine Res : Off J Int Soc Interferon Cytokine Res 36(4):258–266CrossRef
33.
Zurück zum Zitat Salemme R, Peralta LN, Meka SH, Pushpanathan N, Alexander JJ (2019) The role of NETosis in systemic lupus erythematosus. J Cell Immunol 1(2):33–42PubMedPubMedCentral Salemme R, Peralta LN, Meka SH, Pushpanathan N, Alexander JJ (2019) The role of NETosis in systemic lupus erythematosus. J Cell Immunol 1(2):33–42PubMedPubMedCentral
34.
Zurück zum Zitat Pilania RK, Rawat A, Shandilya J, Arora K, Gupta A, Saikia B et al (2022) Pediatric systemic lupus erythematosus: phagocytic defect and oxidase activity of neutrophils. Pediatr Res 92(6):1535–1542CrossRefPubMed Pilania RK, Rawat A, Shandilya J, Arora K, Gupta A, Saikia B et al (2022) Pediatric systemic lupus erythematosus: phagocytic defect and oxidase activity of neutrophils. Pediatr Res 92(6):1535–1542CrossRefPubMed
35.
Zurück zum Zitat Wu SA, Yeh KW, Lee WI, Yao TC, Kuo ML, Huang B et al (2013) Impaired phagocytosis and susceptibility to infection in pediatric-onset systemic lupus erythematosus. Lupus 22(3):279–288CrossRefPubMed Wu SA, Yeh KW, Lee WI, Yao TC, Kuo ML, Huang B et al (2013) Impaired phagocytosis and susceptibility to infection in pediatric-onset systemic lupus erythematosus. Lupus 22(3):279–288CrossRefPubMed
36.
Zurück zum Zitat Suryaprasad A, Stone JH (2008) When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. Arthritis Rheum 59(7):1034–1039CrossRefPubMed Suryaprasad A, Stone JH (2008) When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. Arthritis Rheum 59(7):1034–1039CrossRefPubMed
Metadaten
Titel
Disease activity is associated with changes in the innate immune function in patients with systemic lupus erythematosus
verfasst von
Jiram Torres-Ruiz
Marina Rull-Gabayet
Nancy R. Mejía-Domínguez
Daniel Alberto Carrillo-Vázquez
Juan Alberto Reyes-Islas
Fabiola Cassiano-Quezada
Jennifer Cuellar-Rodríguez
Juan Sierra-Madero
Jessica Márquez Sánchez
Jesús Salvador Serrano-García
Alexia Esquinca González
Guillermo Juárez-Vega
Miguel Tapia-Rodríguez
Diana Gómez-Martín
Publikationsdatum
15.11.2023
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 1/2024
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-023-06810-6

Weitere Artikel der Ausgabe 1/2024

Clinical Rheumatology 1/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.